目的:观察曲妥珠单抗联合化疗治疗表皮生长因子受体-2（HER-2）阳性乳腺癌的临床效果及安全性。方法:选择湖州妇幼保健院2016年1月至2020年1月收治的HER-2阳性乳腺癌患者80例，依据随机数字表法分为观察组（40例）与对照组（40例）。对照组采用多西他赛联合环磷酰胺治疗，观察组在对照组基础上结合曲妥珠单抗治疗。两组均以3周为1个疗程，共6~8个疗程。比较两组近期疗效、化疗前后Karnofsky评分、癌胚抗原（CEA）和糖类抗原153（CA153）水平变化及心脏并发症发生情况。结果:观察组临床控制率（77.50%）高于对照组（55.00%）（χn 2=4.528，n P<0.05）；观察组化疗后Karnofsky评分为（83.19±5.37）分，高于对照组的（75.28±3.78）分（n t=7.618，n P<0.05）；观察组化疗后血清CEA［（6.01±1.34）ng/L］和CA153［（35.12±9.08）U/L］，均低于对照组的（8.32±1.67）ng/L和（49.28±8.27）U/L（n t=6.823、7.292，均n P<0.05）；观察组Ⅱ级以上心脏并发症发生率（30.00%）高于对照组（7.50%）（χn 2=6.646，n P0.05）。n 结论:曲妥珠单抗联合化疗治疗HER-2阳性乳腺癌的近期疗效良好，且可改善患者生存质量，但其Ⅱ级以上心脏并发症发生率较高，故而需进行心功能安全筛选。“,”Objective:To investigate the clinical effect and safety of trastuzumab combined with chemotherapy in the treatment of epidermal growth factor receptor-2-positive breast cancer.Methods:Eighty patients with epidermal growth factor receptor-2 positive breast cancer who received treatment in Huzhou Maternal and Child Health Care Hospital from January 2016 to January 2020 were included in this study. They were randomly assigned to undergo treatment with either docetaxel combined with cyclophosphamide (control group, n n = 40) or docetaxel, cyclophosphamide and trastuzumab (observation group, n n = 40) for 6-8 courses of 3-week treatment. Short-term curative effect, Karnofsky score before and after chemotherapy, serum levels of carcinoembryonic antigen and carbohydrate antigen 153, and cardiac complications were compared between the control and observation groups.n Results:Clinical control rate in the observation group was significantly higher than that in the control group (77.50% n vs. 55.00%, χn 2 = 4.528, n P < 0.05). Karnofsky score after chemotherapy in the observation group was significantly higher than that in the control group [(83.19 ± 5.37) points n vs. (75.28 ± 3.78) points,n t = 7.618, n P < 0.05). Serum carcinoembryonic antigen and carbohydrate antigen 153 levels in the observation group were (6.01 ± 1.34) ng/L and (35.12 ± 9.08) U/L, respectively, which were significantly lower than (8.32 ± 1.67) g/L and (49.28 ± 8.27) U/L, respectively in the observation group ( n t = 6.823, 7.292, both n P < 0.05). The incidence of cardiac complications above grade II in the observation group was significantly higher than that in the control group (30.00% n vs. 7.50%, χn 2 = 6.646, n P 0.05).n Conclusion:Trastuzumab combined with chemotherapy in the treatment of epidermal growth factor receptor-2-positive breast cancer has good short-term curative effect and can improve the quality of life of patients. Nevertheless, it leads to high incidence of cardiac complications above grade II, so it is necessary to perform cardiac safety assessment.